In a landmark move, the Trump administration has launched a sweeping crackdown on misleading pharmaceutical advertisements, the first major enforcement effort since direct-to-consumer drug ads were legalized in 1997.
FDA Commissioner Dr. Marty Makary recently spoke with Full Measure about the unprecedented effort, stating that the agency is sending “thousands” of enforcement letters targeting deceptive promotions across TV, social media, and online platforms.
The U.S. is one of only two countries allowing such ads (the other is New Zealand). Makary says the commercials often downplay serious risks, present false information, or mislead viewers by showcasing happy, dancing patients. He says FDA enforcement has been notoriously lax for decades, with FDA violation letters to drug companies dropping from 130 annually in the late 1990s to zero in 2024.
The new plan targets not just TV but also social media influencers and online pharmacies.
A key focus is closing the “adequate provision loophole,” which allowed vaccine ads to skip disclosing any risks at all by listing them elsewhere, like on websites.
Makary argues this violates regulations against misleading impressions, and the FDA is moving to eliminate it.
No comparable crackdowns on misleading drug ads have ever been launched. Many observers say that’s in part due to the pharmaceutical industry’s influence with members of Congress who get big money from drug companies. They also blame inaction on the media that benefits from all the money drug ads bring in and make them more likely to defend the industry and downplay or censor prescription drug risks and concerns.
Hellbound and Down 